Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02961439
Other study ID # EH2016-133
Secondary ID
Status Completed
Phase N/A
First received November 3, 2016
Last updated August 9, 2017
Start date November 2016
Est. completion date May 1, 2017

Study information

Verified date August 2017
Source Epworth Healthcare
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The use of echocardiography in intensive care is a developing field. In expert hands echocardiography has proven its utility in diagnosing cardiac pathology, differentiating shock states and in haemodynamic monitoring. However, whether the results obtained by experts can be generalized to trainees or specialists with limited training remains unclear. Further, concerns around training time and cost for intensive care staff have been a factor in limiting the uptake of echocardiography in intensive care.

The investigators aim to assess the diagnostic accuracy of Australian ICU doctors in training after completion of the current minimum training. After completing a structured teaching program and 30 mentored training scans trainees will be assessed on their accuracy with echocardiography. In the research phase trainees will complete a further 40 scans with each one matched with an expect scan. The results from the expert and trainee scans will be compared to determine the trainee's accuracy.


Recruitment information / eligibility

Status Completed
Enrollment 252
Est. completion date May 1, 2017
Est. primary completion date May 1, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Registrar Inclusion:

- At least 12 month appointment in Epworth Richmond ICU

- Completion of theoretical component of Epworth Richmond ICU echocardiography program

- Completion of 30 echocardiography scans

Registrar Exclusion:

• Previous experience in echocardiography prior to commencing at Epworth Richmond.

Patient Inclusion

- Patient in ICU or CCU

- 18 years or older

- Not likely to be discharged before completion of the scan

Patient Exclusion

- Likely to be discharged within next two hours

- Atrial fibrillation

- Presence of subcostal or intercostal drains or pneumothorax

- Unable to be consented

- Treating intensivist deems inclusion in study not suitable.

Study Design


Intervention

Behavioral:
Epworth Richmond's Echocardiography Focused Year
a year long echo teaching program

Locations

Country Name City State
Australia Epworth Richmond Melbourne Victoria

Sponsors (2)

Lead Sponsor Collaborator
Epworth Healthcare University of Melbourne

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Agreement between registrar and expert assessment of Left ventricular (LV) function Four months
Secondary Comparison of expert and registrar quantitative measures of Left vwentricular Internal Diameter in Diastole (LVIDd) Four months
Secondary Comparison of expert and registrar quantitative measures of Left Ventricular Outflow Tract (LVOT) diameter Four months
Secondary Comparison of expert and registrar quantitative measures of Left Ventricular Outflow Tract Velocity Time Integral (LVOT VTI) Four months
Secondary Comparison of expert and registrar quantitative measures of TR V max Four months
Secondary Comparison of expert and registrar quantitative measures of Tricuspid annular Plane Systolic Excursion (TAPSE) Four months
Secondary Comparison of expert and registrar quantitative measures of IVC diameter Four months
Secondary Comparison of expert and registrar qualitative assessment of pericardial fluid Four months
Secondary Comparison of expert and registrar qualitative assessment of Left Ventricle : Right Ventricle size ratio Four months
See also
  Status Clinical Trial Phase
Recruiting NCT05050617 - Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Completed NCT03915925 - Short-term Clinical Deterioration After Acute Pulmonary Embolism
Completed NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Recruiting NCT05171075 - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3
Completed NCT04454554 - Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
Completed NCT03173066 - Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography Phase 1
Terminated NCT03002467 - Impact Analysis of Prognostic Stratification for Pulmonary Embolism N/A
Completed NCT02611115 - Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography. N/A
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT01975090 - The SENTRY Clinical Study N/A
Not yet recruiting NCT01357941 - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) N/A
Completed NCT01326507 - Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism N/A
Completed NCT00771303 - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed NCT02476526 - Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease Phase 4
Completed NCT00780767 - Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism Phase 2
Completed NCT00720915 - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months N/A
Completed NCT00773448 - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism N/A
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2